GLP-1 Research: Semaglutide vs Tirzepatide

No two peptides have done more to energize the field than semaglutide and tirzepatide. In metabolic research they are the central comparison - and understanding how they differ is essential context for the category.

The incretin system

Both peptides act on the incretin system - the gut-hormone signals that influence insulin response and satiety. The key difference is how many incretin pathways each engages.

Semaglutide: single-pathway GLP-1

Semaglutide is a long-acting GLP-1 receptor agonist. Research focuses on GLP-1-mediated glucose-dependent insulin signaling, slowed gastric emptying, and central satiety pathways. Its long half-life makes it a clean, well-characterized model for single-pathway incretin research.

Tirzepatide: dual GLP-1/GIP

Tirzepatide adds a second pathway. It is a dual agonist that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Engaging two incretin pathways at once is the defining research distinction, and it is why tirzepatide is studied as a step beyond single-pathway models.

How researchers choose between them

The choice is a research-design question, not a ranking. Single-pathway studies use semaglutide to isolate GLP-1 signaling; dual-pathway studies use tirzepatide to examine the combined incretin effect. Head-to-head comparisons of the two are themselves a major research theme.

The research-use framework still applies

Whatever the mechanism, both compounds are supplied for laboratory research only. They are not for human consumption, are not FDA-approved for any use sold here, and any dosing references describe laboratory titration models, not instructions for living subjects.

Frequently asked questions

All guides · Order research peptides

External references: U.S. Food and Drug Administration · Peptide (Wikipedia)